Business Context and Reporting Period
Company: Apimeds Pharmaceuticals US, Inc. (APUS)
Reporting Period: Quarter ended March 31, 2025 (Form 10-Q)
Business Overview: A clinical-stage biopharmaceutical company developing Apitox, a bee venom-based therapeutic for osteoarthritis and multiple sclerosis. The company is pre-revenue and dependent on regulatory approvals and financing.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(402,397) | $(296,473) |
| Loss Per Share (Basic/Diluted) | $(0.05) | $(0.04) |
| Cash and Equivalents (End of Period) | $250,342 | $147,381 |
| Working Capital Deficit | $(1,136,898) | Not explicitly stated |
| Total Liabilities | $2,020,422 | $1,371,178 |
| Accumulated Deficit | $(4,794,321) | $(3,298,407) |
Cash Flow Summary (Q1 2025):
- Net cash used in operating activities: $(20,313)
- Net cash provided by financing activities: $267,200 (primarily related party notes)
- Net increase in cash: $246,887
Material Changes vs. Prior Period
- Increased Operating Expenses: General and administrative expenses rose by $92,642 (34% increase) to $364,368, driven by a $95,454 increase in professional services (SEC filing and pre-IPO costs) and a $7,500 increase in payroll.
- Higher Interest Expense: Total interest expense increased by $11,124 to $38,032 due to accretion on convertible notes and related party debt.
- Debt Structure: The company incurred new related-party debt in Q1 2025, including a $250,000 promissory note and $17,200 in cash advances, increasing total liabilities significantly compared to the prior year.
- Stock Split: A 1-for-2.6 reverse stock split was implemented on February 7, 2025; all share data is retrospectively adjusted.
Guidance, Outlook, and Subsequent Events
Subsequent Event - IPO: On May 12, 2025, the company consummated its Initial Public Offering (IPO), selling 3,375,000 shares at $4.00 per share. This generated gross proceeds of $13.5 million and net proceeds of approximately $11.9 million.
Debt Conversion: In connection with the IPO, $772,545 of outstanding principal and accrued interest from 2021 and 2022 convertible notes automatically converted into 297,133 shares of common stock.
Liquidity Outlook: Management believes the IPO proceeds, combined with existing cash, are sufficient to fund operations for at least the next twelve months.
Risks and Controls:
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2025, citing material weaknesses including a lack of documented procedures, segregation of duties, and review controls.
- Related Party Dependence: A significant portion of debt and funding comes from related parties (Apimeds Korea, Inscobee Inc.).
Investor Verification Checklist
- IPO Proceeds Utilization: Verify the actual net cash received from the May 2025 IPO and confirm the timeline for deployment into clinical trials.
- Debt Obligations: Confirm the status of remaining related-party promissory notes (2024 and 2025 notes) which were amended to mature in May 2026.
- Internal Control Remediation: Review the company's plan to address the material weaknesses in internal controls over financial reporting identified in this filing.
- Regulatory Status: Verify the current status of FDA discussions regarding Apitox approval for osteoarthritis and the timeline for potential MS studies.
- Stock-Based Compensation: Monitor the vesting schedule and grant details for the CEO's incentive stock options triggered by the IPO.